Get the Stockscreener App
17.14
0.47%
0.08
After Hours:
17.14
Spyre Therapeutics Inc stock is traded at $17.14, with a volume of 329.48K.
It is up +0.47% in the last 24 hours and down -3.65% over the past month.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
See More
Previous Close:
$17.06
Open:
$16.91
24h Volume:
329.48K
Relative Volume:
0.60
Market Cap:
$1.04B
Revenue:
$1.23M
Net Income/Loss:
$-214.90M
P/E Ratio:
-4.158
EPS:
-4.1222
Net Cash Flow:
$-151.25M
1W Performance:
+4.83%
1M Performance:
-3.65%
6M Performance:
-6.70%
1Y Performance:
-38.37%
1-Day Range:
$16.89
$17.34
1-Week Range:
$15.91
$17.80
52-Week Range:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Compare SYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
17.14 | 1.03B | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | Leerink Partners | Outperform |
| Mar-18-25 | Initiated | Wolfe Research | Outperform |
| Sep-04-24 | Initiated | Wedbush | Outperform |
| Jul-16-24 | Initiated | Evercore ISI | Outperform |
| May-02-24 | Initiated | Robert W. Baird | Outperform |
| Mar-01-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
Real time scanner hits for Spyre Therapeutics Inc. explainedGold Moves & AI Forecast for Swing Trade Picks - Newser
What technical models suggest about Spyre Therapeutics Inc.’s comeback - Newser
Is Spyre Therapeutics Inc. trending in predictive chart modelsQuarterly Profit Review & Accurate Buy Signal Alerts - Newser
Market reaction to Spyre Therapeutics Inc.’s recent news2025 Year in Review & Fast Exit and Entry Strategy Plans - Newser
Long term hold vs stop loss in Spyre Therapeutics Inc.Weekly Trade Analysis & Reliable Trade Execution Plans - Newser
Relative strength of Spyre Therapeutics Inc. in sector analysisAnalyst Upgrade & Free Expert Verified Stock Movement Alerts - Newser
Spyre Therapeutics Inc. stock trend forecastJuly 2025 Analyst Calls & Precise Buy Zone Tips - Newser
What data driven models say about Spyre Therapeutics Inc.’s futureGap Up & Consistent Profit Focused Trading Strategies - Newser
Can Spyre Therapeutics Inc. recover in the next quarterQuarterly Portfolio Review & Proven Capital Preservation Methods - Newser
Is Spyre Therapeutics Inc. forming a bottoming baseTrade Signal Summary & Free Accurate Trade Setup Notifications - Newser
Published on: 2025-08-25 08:43:40 - Newser
Using flow based indicators on Spyre Therapeutics Inc.Weekly Risk Summary & Growth Focused Stock Reports - Newser
Combining machine learning predictions for Spyre Therapeutics Inc.Earnings Risk Summary & Reliable Trade Execution Plans - Newser
Traders Consider Averaging Down in Spyre Therapeutics Inc.2025 Macro Impact & Step-by-Step Swing Trade Plans - newsyoung.net
Activity Recap: What’s the RSI of Spyre Therapeutics Inc. stock2025 Key Highlights & Free Community Consensus Stock Picks - sundaytimes.kr
Is Spyre Therapeutics Inc. stock technically oversoldJuly 2025 Rallies & Risk Controlled Stock Alerts - sundaytimes.kr
Will Spyre Therapeutics Inc. bounce back from current supportProduct Launch & Real-Time Stock Movement Alerts - Newser
What is Spyre Therapeutics Inc.’s valuation compared to sector2025 Market Sentiment & Community Verified Trade Alerts - theviewers.co.kr
FOMO Trade: What are the future prospects of Spyre Therapeutics Inc.Market Growth Report & AI Driven Stock Price Forecasts - sundaytimes.kr
Spyre Therapeutics Inc. stock trend outlook and recovery path2025 Market Overview & Accurate Buy Signal Alerts - Newser
Does Spyre Therapeutics Inc. have high return on assetsDay Trade & Verified Technical Signals - theviewers.co.kr
Spyre Therapeutics Bets Big On Next-Gen IBD Pipeline - Finimize
Can Spyre Therapeutics Inc. expand its profit marginsEarnings Growth Summary & Daily Growth Stock Investment Tips - sundaytimes.kr
Spyre Therapeutics Inc. stock retracement – recovery analysisTake Profit & Consistent Growth Equity Picks - Newser
How hedge fund analytics apply to Spyre Therapeutics Inc. stockEarnings Beat & Accurate Technical Buy Alerts - Newser
Custom Dashboard Highlights Spyre Therapeutics Inc. Price MomentumMarket Growth Report & Long-Term Growth Plans - kangso.co.kr
When is the best time to exit Spyre Therapeutics Inc.Market Performance Summary & Advanced Technical Signal Analysis - Newser
Analyzing net buyer seller activity in Spyre Therapeutics Inc.July 2025 Sector Moves & Fast Entry and Exit Trade Plans - Newser
How to build a dashboard for Spyre Therapeutics Inc. stock2025 Historical Comparison & Accurate Intraday Trade Tips - Newser
RSI + MACD Show Convergence for Spyre Therapeutics Inc.2025 Valuation Update & Consistent Income Trade Ideas - newsyoung.net
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):